Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Lipoxal

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
BACKGROUND: Clinical testing of new therapeutic interventions requires comprehensive, high-quality preclinical data. Concerns… 
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2016
2016
SummaryResults of clinical trials with oxaliplatin in treating glioblastoma are dismal. Previous works showed that intravenous (i… 
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Review
2014
Review
2014
Introduction: To date, a growing number of advanced anticancer nanomedicines (e.g., Doxil®, Lipoxal®, DepoCyte®) have entered… 
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • figure 4
2014
2014
AIM To determine the benefits of irradiation at the time of maximum linking of oxaliplatin to the DNA of tumor cells, and… 
2013
2013
AbstractTreatment of glioblastoma with platinum compounds modestly improves progression-free survival and may cause toxic effects… 
  • figure 1
  • table 1
  • figure 2
  • figure 3
2012
2012
PURPOSE Treatments of glioblastoma with cisplatin or oxaliplatin only marginally improve the overall survival of patients and… 
2012
2012
BACKGROUND We choose to test the effect of associating chemo-radiotherapy at 8 h (the highest level of DNA-platinum) and 48 h… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2010
Highly Cited
2010
SummaryLiposomal formulations of cisplatin and oxaliplatin (Lipoplatin™ and Lipoxal™, respectively) were recently proposed to… 
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
2006
2006
Lipoplatin, currently under phase III evaluation, is a novel liposomal cisplatin formulation highly effective against cancers… 
Highly Cited
2006
Highly Cited
2006
BACKGROUND Lipoxal is a liposomal oxaliplatin, which reduces the cytotoxic agent's adverse reactions without reducing… 
  • table I
  • table II
  • table III
  • figure 1
  • figure 2